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patients out of total 835 patients reported. In pediatric cohort
165 patients suffered from malignancies, 356 patients were
transplanted for non-malignant diseases; 437 underwent a
ﬁrst SCT, 87 had a subsequent transplant. In adult group 626
were treated for hematological malignancies and 18 for non-
malignant diseases (SAA or thalassemia). No data on auto-
SCT in adults were published after 2004. The majority of
pediatric patients received treosulfan in dose 39-45 mg/m2
(332 patients, 62%). Most of adult patients treated after 2007
received dose of 42 mg/m2.
Results: The main indications for treosulfan use in pediatric
population were non-malignant diseases (68%) or second
SCT, while among adults older age (>50 years) and/or
comorbidities disqualifying from myeloablative condition-
ing. No correlation between the given treosulfan dose and
the grade III/IV toxicity was observed both in children and in
adults. No association between dose and GVHD, OS, DFS,
relapse incidence and TRMwas found both in children and in
adults.
Conclusions: Treosulfan-based conditioning with its low
toxicity proﬁle and dose-dependent myelotoxicity is a good
option in children treated with non-malignant diseases.
Additionally, both children and adults not eligible for con-
ventional transplant regimen can be offered this treatment
with acceptable results. Toxicity and survival were similar in
children and adults, while acute and chronic GVHD incidence
were higher in adult population.391
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Donor-derived malignancy (DDM) is a rare but often fatal
complication of alloBMT, with a reported incidence of 0.1-5%.
AlloBMT utilizing high-dose post-transplantation cyclo-
phosphamide (PT/Cy) as GVHD prophylaxis produces excel-
lent rates of engraftment and low rates of acute and chronic
GVHD. Because exposing the allograft to cytotoxic chemo-
therapy may theoretically increase the risk of DDM, we
evaluated the incidence of DDM after alloBMT with PT/Cy.
From 2000-2012, 790 patients (median age 51y, range 1-74y)
received T-cell replete alloBMT with high-dose PT/Cy at
Johns Hopkins, including 313 (40%) who received PT/Cy as
sole GVHD prophylaxis. Of these transplants, 349 (44%) were
HLA-haploidentical and 346 (44%) were myeloablative. Me-
dian donor age was 41y (range 13-79y). With a median
follow-up of 3y (range, 0.8-9.4y) in patients without events,
the 3 year PFS and OS probabilities were 42% and 56%
respectively. Five cases (5/790¼0.6%) of DDMwere identiﬁedas well as one case of clonal, donor-derived LGL leukemia
that resolved without any therapy. By competing-risk anal-
ysis, the probability of DDM was 0.6% at 1 y, 0.8% at 5 y, and
2% overall (Figure). In the 5 identiﬁed cases of DDM, the
median patient age was 41y (range 18-65 y) at BMT and
median donor age was 41y (31-67y). These patients were
initially transplanted for ALL (1), NHL (3), or Hodgkin lym-
phoma (1). Two patients received myeloablative condition-
ing and 3 received additional GVHD prophylaxis with
mycophenolate mofetil and tacrolimus. The median time
from BMT to the diagnosis of DDMwas 1.3y (range 0.5-6.3y).
DDMs consisted ofMDS (1), AML (3), and CMML (1). All of the
patients received treatment for their DDM; 2 are long term
survivors and 3 died of their DDM. The incidence of devel-
oping a DDM after high-dose PT/Cy is rare, and is within the
range reported for other transplant platforms.392
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is the only potentially curative treat-
ment option for MF. The role of ex evivo TCD allo-HSCT
hasn’t been reported in patients with advanced MF.
Patients: Between 5/1990-4/2013, 12 pts underwent TCD
transplant at MSKCC for MF; 9 had primary MF, 2 post ET and
1 post MDS. Median age was 56 (42.7-65.5). Disease status
prior to transplant per DIPSS was: intermediate-1 (4), inter-
mediate-2 (6), and high-risk (2). Splenectomy prior to
transplant was performed in 8 patients. JAK2 V617Fmutation
status was known on ﬁve patients and was detected on 3.
Five pts received a TCD marrow graft and were conditioned
with a TBI-based regimen and 7 pts received TCD peripheral
blood graft and were conditioned with a chemotherapy
